2023-07-28 15:43:11
2023-07-28 23:43 Economic Daily reporter Wei Xinyang / Taipei Report
Sinopharm (6446) defended its stock price yesterday (28th) when the board of directors announced the decision to implement treasury stocks once more. It is scheduled to start from July 31 to September 29, and the plan is to be in the range of 350 to 450 yuan. It is expected to buy back 4,000 shares. The upper limit of the amount does not exceed 1.8 billion yuan, accounting for 1.18% of the number of issued shares; the purpose of buying back shares is to transfer shares to employees.
This is the second time that Sinopharm has implemented treasury stocks this year. The last implementation period was from May 26 to July 21. The estimated number of shares bought back was 5,000, but the actual number of shares bought back was 4,001, and the implementation status was 80.02%.
In addition, Yaohua Pharmaceutical previously implemented treasury stocks from January 8 to March 5, 2021. It is planned to buy back 1,500 shares, but the actual number of shares bought back is 904, and the implementation status is 60.27%. And, from October 29 to December 25, 2020, treasury stocks will be implemented. The number of shares repurchased is 3,200, and the actual number of shares repurchased is 2,935. The implementation status is 91.72%.
Benefiting from the buoyant global sales of Ropeginterferon alfa-2b (Ropeg for short), a new rare blood cancer drug, and the Japanese market has also started to contribute revenue since June, the revenue of Sinopharm in June soared to 509 million yuan, setting a record high. The monthly increase was 21.7%, and the annual increase was 84.03%.
Sinopharm treasury stocks
further reading
1690617035
#Yaohua #Pharmaceutical #implement #treasury #stocks #storefront #unlisted #stock #market
